HIV-1 Tropism

Abstract

104bLB. 32. Nelson M, Fatkenheuer G, Konourina I et al.: Efficacy and safety of maraviroc plus optimised background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24 week results. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007, Abstract 104aLB. 33. Lalezari J, Mayer H: Efficacy and safety of maraviroc (MVC) in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1. Presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007. 34. Mayer H, van der Ryst E, Saag M et al.: Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretroviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24 week results of a Phase 2b exploratory trial. Presented at: XVI International AIDS Conference. Toronto, Canada, 13–18 August 2006, Abstract THLB0215. 35. Schuitemaker H, Koot M, Kootstra N et al.: Biological phenotype of HIV type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66, 1354–1360 (1992). 36. Connor R, Sheridan K, Ceradini D, Choe S, Landay N: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621–628 (1997). 37. Daar ES, Kesler KL, Petropoulos CJ et al.: Baseline HIV type 1 coreceptor tropism predicts disease progression. 45(5), 643–649